![Deegtal Deegtal](https://bioalps.org/app/uploads/2024/08/Deegtal.png)
dEEGtal receives CHF 10’000 from Venture Kick
![](https://bioalps.org/app/uploads/2018/07/icon-line-bicolor.png)
Share this article
dEEGtal, who is developing a software for epilepsy diagnosis, has received Venture Kick’s first financial and entrepreneurial support stage with CHF 10’000.
The diagnosis of epilepsy is mostly based on visual interpretation of the electroencephalogram (EEG). This method inherently does not provide a diagnosis in 75-80% of the cases, making the diagnosis challenging, in turn affecting patients’ quality of life and worsening their prognosis.
dEEGtal stems from Dr. Eric Ménétré and Dr. Stefano Gallotto who, by bringing together expertise in clinical research, neuroscience, and AI, are developing a software to assist neurologists in the diagnosis of epilepsy.
The software extracts information from the EEG that is not available with current EEG reading methods and provides an AI-calculated risk-score of epilepsy. In a growing global epilepsy diagnostics market valued at $3.3 billion, dEEGtal is part of an environment that provides a substantial opportunity for growth.
Securing the first stage of Venture Kick funding will enable dEEGtal to conduct thorough market research and validate their market entry, regulatory and IP strategies. This will set the stage for successful market entry.
Source: press release